{"id":540,"date":"2025-12-03T08:41:35","date_gmt":"2025-12-03T08:41:35","guid":{"rendered":"https:\/\/www.saiep-paris.fr\/?p=540"},"modified":"2026-10-30T22:37:40","modified_gmt":"2026-10-30T22:37:40","slug":"call-for-proposals-shanghai-sci-tech-co-research-program-3","status":"publish","type":"post","link":"https:\/\/www.saiep-paris.fr\/en\/call-for-proposals-shanghai-sci-tech-co-research-program-3.html","title":{"rendered":"&#8220;Innovate in Shanghai&#8221; Finals Winners Announced! Promoting Innovation through Competition and Helping Enterprises Advance from Innovation to Industrialization"},"content":{"rendered":"<p><strong>&#8220;The competition has provided us with a valuable platform to showcase our project, which is crucial for a company like ours that focuses on original drug research and development. At the same time, it has connected our company with many excellent resources,&#8221; said Ma Wenjiang, co-founder and CEO of Shanghai Shijiang Biotechnology Co., Ltd.<\/strong><\/p>\n<p>\u00a0<\/p>\n<p><strong>When the seeds of innovation land in Shanghai, what kind of growth journey do they go through? Recently, at the finals of the 2025 &#8220;Innovate in Shanghai&#8221; International Innovation and Entrepreneurship Competition \u2014 guided by the organizing committee of the &#8220;Innovate in Shanghai&#8221; International Innovation and Entrepreneurship Competition and hosted by the Shanghai Technology Entrepreneurship Center \u2014 50 hard-core science and technology enterprises gave their answers through their own practice. The finals were not only a contest of scientific and technological achievements, but also an answer sheet on &#8220;how to make innovation go further.&#8221;<span data-pm-slice=\"1 1 [&quot;para&quot;,{&quot;tagName&quot;:&quot;section&quot;,&quot;attributes&quot;:{&quot;style&quot;:&quot;box-sizing: border-box;font-style: normal;font-weight: 400;text-align: justify;&quot;},&quot;namespaceURI&quot;:&quot;http:\/\/www.w3.org\/1999\/xhtml&quot;},&quot;para&quot;,{&quot;tagName&quot;:&quot;p&quot;,&quot;attributes&quot;:{&quot;style&quot;:&quot;white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;font-style: normal;font-weight: 400;text-align: justify;font-size: 16px;color: rgb(62, 62, 62);&quot;},&quot;namespaceURI&quot;:&quot;http:\/\/www.w3.org\/1999\/xhtml&quot;}]\">After the competition, the list of winners of the 2025 &#8220;Innovate in Shanghai&#8221; International Innovation and Entrepreneurship Competition finals was announced.<\/span><\/strong><\/p>\n<p><strong>Reprinted from Shanghai Science and Technology<\/strong><\/p>\n<p><strong>&#8220;The competition has provided us with a valuable platform to showcase our project, which is crucial for a company like ours that focuses on original drug research and development. At the same time, it has connected our company with many excellent resources,&#8221; said Ma Wenjiang, co-founder and CEO of Shanghai Shijiang Biotechnology Co., Ltd.<\/strong><\/p>\n<p>\u00a0<\/p>\n<p><strong>When the seeds of innovation land in Shanghai, what kind of growth journey do they go through? Recently, at the finals of the 2025 &#8220;Innovate in Shanghai&#8221; International Innovation and Entrepreneurship Competition \u2014 guided by the organizing committee of the &#8220;Innovate in Shanghai&#8221; International Innovation and Entrepreneurship Competition and hosted by the Shanghai Technology Entrepreneurship Center \u2014 50 hard-core science and technology enterprises gave their answers through their own practice. The finals were not only a contest of scientific and technological achievements, but also an answer sheet on &#8220;how to make innovation go further.&#8221;<span data-pm-slice=\"1 1 [&quot;para&quot;,{&quot;tagName&quot;:&quot;section&quot;,&quot;attributes&quot;:{&quot;style&quot;:&quot;box-sizing: border-box;font-style: normal;font-weight: 400;text-align: justify;&quot;},&quot;namespaceURI&quot;:&quot;http:\/\/www.w3.org\/1999\/xhtml&quot;},&quot;para&quot;,{&quot;tagName&quot;:&quot;p&quot;,&quot;attributes&quot;:{&quot;style&quot;:&quot;white-space: normal;margin: 0px;padding: 0px;box-sizing: border-box;font-style: normal;font-weight: 400;text-align: justify;font-size: 16px;color: rgb(62, 62, 62);&quot;},&quot;namespaceURI&quot;:&quot;http:\/\/www.w3.org\/1999\/xhtml&quot;}]\">After the competition, the list of winners of the 2025 &#8220;Innovate in Shanghai&#8221; International Innovation and Entrepreneurship Competition finals was announced.<\/span><\/strong><\/p>\n<p><strong><img referrerpolicy=\"no-referrer\" decoding=\"async\" src=\"https:\/\/www.saiep-paris.fr\/wp-content\/uploads\/2026\/10\/1112.jpg\" alt=\"\" \/><\/strong><\/p>\n<p>\u00a0<\/p>\n<section>\n<section>\n<section>\n<p><strong>When Entrepreneurship Chooses to Tackle the &#8220;Hard&#8221; Bones<\/strong><\/p>\n<\/section>\n<\/section>\n<\/section>\n<section>\n<p>When entrepreneurs are not content with &#8220;innovation for innovation&#8217;s sake&#8221; and choose to break new ground in uncharted territory and cultivate the foundations, these stories took on a more concrete shape on the stage of the 2025 &#8220;Innovate in Shanghai&#8221; competition.<\/p>\n<p dir=\"rtl\"><img referrerpolicy=\"no-referrer\" decoding=\"async\" src=\"https:\/\/www.saiep-paris.fr\/wp-content\/uploads\/2026\/10\/1111.jpg\" alt=\"\" \/><\/p>\n<section>\n<section>\n<section>\n<p>&#8220;Developing truly original new drugs is like breaking new ground in uncharted territory,&#8221; Ma Wenjiang pointed out. Today China already has deep scientific research accumulation in the biopharmaceutical field and possesses the strength to tackle global challenges. Shijiang Biotech is targeting the most intractable clinical problem of malignant tumor recurrence; relying on solid basic research accumulation, it insists on developing truly original new drugs, aiming to compete on the same stage with international pharmaceutical giants and to rank at the forefront of the global innovation race.<\/p>\n<p>\u00a0<\/p>\n<p>Glioma, known as the &#8220;number one killer&#8221; in the field of brain cancer, is dangerous because of the lack of effective treatments. Even after surgery to remove the tumor as much as possible, supplemented by radiotherapy and chemotherapy, the tumor still has a very high probability of rapidly recurring in situ. Once it recurs, doctors and patients both face a &#8220;nothing can be done&#8221; dilemma, which has also become an unsolved problem worldwide.<\/p>\n<p>\u00a0<\/p>\n<p>Faced with such a challenge, Ma Wenjiang&#8217;s confidence comes from the team&#8217;s more than 20 years of solid basic research accumulation. &#8220;We not only have a deep understanding of the tumor stem cells that drive glioma recurrence, but have also discovered a reliable druggable mechanism on this basis, which gives us our greatest confidence.&#8221; This confidence derived from science has been transformed into a firm belief: &#8220;Drugs that target tumor stem cells directly address the pain points of tumor drug resistance and recurrence; they not only meet huge market demand, but will also open up a new anti-cancer path with broad-spectrum potential.&#8221; According to the company, the first-class innovative drug targeting tumor stem cells developed by Shijiang Biotech is about to enter the clinical stage. The drug is dedicated to addressing the highly unmet clinical needs of patient groups such as those with glioma and pancreatic cancer, and is expected to fundamentally solve the problem of malignant tumor recurrence.<\/p>\n<p>\u00a0<\/p>\n<p><img referrerpolicy=\"no-referrer\" decoding=\"async\" src=\"https:\/\/www.saiep-paris.fr\/wp-content\/uploads\/2026\/10\/1113.jpg\" alt=\"\" \/><\/p>\n<\/section>\n<\/section>\n<\/section>\n<p>\u00a0<\/p>\n<p>When too many people chase the latest trend, another group of entrepreneurs chooses to return to the origins of the industry. Yang Hao, CEO of Qingxin Semiconductor, admitted that the development of AI has brought unprecedented computing power demand to the industry, and &#8220;high-performance, low-latency interconnection has become an important issue.&#8221;<\/p>\n<section>\n<p>\u00a0<\/p>\n<p>&#8220;What our team often talks about is not innovation, but solid engineering work.&#8221; In Yang Hao&#8217;s view, &#8220;the scientific questions in the chip field are not that mysterious; they are more about the combination and solid evolution of engineering technologies.&#8221; This clear understanding of the industry led his team to choose a path that seems clumsy but is more steady. He has always believed that innovation needs a foundation: &#8220;Innovation is the next step, but if an enterprise is obsessed only with innovation, it will give up a lot of basic work. A flash of inspiration is only the starting point; only by moving forward solidly can final success be achieved.&#8221;<\/p>\n<p>\u00a0<\/p>\n<\/section>\n<section>\n<section>\n<section>\n<p><strong>How Does Hard Tech Make a &#8220;Soft Landing&#8221;?<\/strong><\/p>\n<\/section>\n<\/section>\n<\/section>\n<section>\n<p>\u00a0<\/p>\n<p>The passion and ideals of entrepreneurship are only a prologue. True hard-tech innovation tests how enterprises transform complex technology paths, layer by layer, into usable products and continue to go deeper and more solidly under the test of industry and market.<\/p>\n<p><img referrerpolicy=\"no-referrer\" decoding=\"async\" src=\"https:\/\/www.saiep-paris.fr\/wp-content\/uploads\/2026\/10\/1114.jpg\" alt=\"\" \/><\/p>\n<p>\u00a0<\/p>\n<section>\n<p>\u00a0<\/p>\n<\/section>\n<section>\n<p>A relevant person in charge of YolTech Therapeutics admitted that a key advantage of the team lies in &#8220;the organic combination of the most cutting-edge scientific research and industrial transformation.&#8221; YolTech has always regarded industrialization and clinical translation as its core goals: &#8220;In vivo gene editing drugs represent the forefront of pharmaceutical research. But for this most innovative technology to truly become a drug, basic research at the laboratory stage alone is far from enough. It is necessary to combine a solid underlying research platform, a deep understanding of diseases and commercialization prospects, and an international strategic vision to ultimately produce drugs that truly meet clinical needs and lead internationally.&#8221;<\/p>\n<p>\u00a0<\/p>\n<p>Compared with traditional cell and gene therapies, in vivo gene editing drugs have become a new research and development hotspot in the CGT field thanks to potential advantages such as convenient administration, broad indications, good safety, low production costs, and one-shot cure. As one of the innovative enterprises focusing on in vivo gene editing drugs, YolTech has advanced five pipeline products to the clinical stage, covering a variety of rare and common diseases, and has become the in vivo gene editing drug development company with the most pipelines in the clinical stage worldwide. In June this year, the company&#8217;s second product, YOLT-101, for the treatment of hyperlipidemia, successively obtained IND approval from the US FDA and China&#8217;s NMPA, becoming China&#8217;s first in vivo base editing therapy approved for clinical trials in both China and the United States, and several products have obtained orphan drug designation in the EU and the United States respectively.<\/p>\n<p>\u00a0<\/p>\n<p>&#8220;For biopharmaceutical companies, innovation is only meaningful if they persist in continuously transforming innovative technologies into products that can be implemented and benefit more patients.&#8221; In YolTech&#8217;s view, only by truly connecting the &#8220;last mile&#8221; between research and industry can the seeds of hard tech take root and sprout in the soil.<\/p>\n<p>\u00a0<\/p>\n<p>It is reported that this year, the research project &#8220;Development and Translational Application of Key Technologies for Gene Editing and Cell Therapy&#8221;, jointly declared by East China Normal University, Bangyao Biotech and YolTech, won the &#8220;First Prize of the 2024 Shanghai Science and Technology Progress Award&#8221;.<\/p>\n<p>\u00a0<\/p>\n<\/section>\n<section>\n<section>\n<section>\n<p><strong>Beyond the Arena, a Magnetic Field Matters More<\/strong><\/p>\n<\/section>\n<\/section>\n<\/section>\n<section>\n<p>\u00a0<\/p>\n<p>While batch after batch of entrepreneurs tackle the &#8220;hard&#8221; bones and team after team practices &#8220;soft landing&#8221;, the city&#8217;s support system is quietly building a magnetic field behind the scenes to push these hard-tech enterprises to grow upward. For many founders, Shanghai is not just a city but the birthplace of innovative dreams, and the &#8220;Innovate in Shanghai&#8221; competition is an important platform connecting dreams with reality.<\/p>\n<p><img referrerpolicy=\"no-referrer\" decoding=\"async\" src=\"https:\/\/www.saiep-paris.fr\/wp-content\/uploads\/2026\/11\/1115.jpg\" alt=\"\" \/><\/p>\n<p>As a science and technology innovation competition held in Shanghai for thirteen consecutive editions, the &#8220;Innovate in Shanghai&#8221; International Innovation and Entrepreneurship Competition has become a key pillar for the growth of technology-based small and medium-sized enterprises and the building of an innovation ecosystem. This year, the competition has been comprehensively upgraded: it not only opened for the first time to enterprises from outside Shanghai, but also continued to deepen its internationalization and increased support for entrepreneurial teams and start-ups. It also joined hands with national strategic scientific and technological forces, high-quality incubators and leading enterprises to set up industry-specific competitions in artificial intelligence, integrated circuits, biomedicine and other fields, pushing the &#8220;year-round competition, full-coverage&#8221; model ever deeper.<\/p>\n<p>\u00a0<\/p>\n<p><img referrerpolicy=\"no-referrer\" decoding=\"async\" src=\"https:\/\/www.saiep-paris.fr\/wp-content\/uploads\/2026\/10\/1116.jpg\" alt=\"\" \/><\/p>\n<p>\u00a0\u00a0<\/p>\n<section>\n<p>For innovative enterprises, Shanghai&#8217;s innovation ecosystem goes beyond policy support and is reflected in the coordinated efforts of the entire chain of talent, capital and environment. Yang Wentao, founder of Haihuan Technology, feels this deeply: &#8220;Shanghai has a great entrepreneurial atmosphere \u2014 fast-paced, dynamic and full of imagination.&#8221; He said that the growth of an enterprise cannot be separated from government coordination; policy guidance and subsidies bring tangible benefits, and what is even more rare is the inclusiveness and diversity here. &#8220;Our team comes from all over the world and has come to &#8216;Innovate in Shanghai&#8217;, yet everyone can settle down with peace of mind. This is not only where dreams begin, but also a place where you can blossom.&#8221;<\/p>\n<p>\u00a0<\/p>\n<p>The &#8220;magnetic field effect&#8221; of the competition far exceeds the &#8220;competition&#8221; itself. In interviews, Yang Wentao mentioned that many key investment and financing matchmakings were realized precisely through the competition: &#8220;The competition has enabled us to meet like-minded peers and mentors, as well as quite a few industrial investors.&#8221; This continuous empowerment both inside and outside the arena has become the reason why countless entrepreneurs stay in Shanghai and grow upward.<\/p>\n<p>\u00a0<\/p>\n<p><img referrerpolicy=\"no-referrer\" decoding=\"async\" src=\"https:\/\/www.saiep-paris.fr\/wp-content\/uploads\/2026\/10\/1117.jpg\" alt=\"\" \/><\/p>\n<\/section>\n<p>\u00a0<\/p>\n<section>\n<p>In addition to policies and capital, the city&#8217;s &#8220;magnetic field&#8221; is also reflected in the diversified and open nature of innovation resources. Wen Liang, Chief Operating Officer of Likr Technology, said that the professional judges and industry matchmaking resources of the competition platform give enterprises the opportunity to engage deeply with upstream and downstream partners and industrial capital. &#8220;This event provides us with a very large platform: it offers links to partners and lets us see the support across the entire ecosystem, so that we can better strengthen our capacity for horizontal market development.&#8221;<\/p>\n<section data-mpa-action-id=\"mi2wzuyd9ff\" data-pm-slice=\"0 0 []\"><\/section>\n<section data-pm-slice=\"0 0 []\">\n<section>\n<p><strong>Let&#8217;s Take a Look at the Winners List<\/strong><\/p>\n<p>\u00a0<\/p>\n<p><strong><img referrerpolicy=\"no-referrer\" decoding=\"async\" src=\"https:\/\/www.saiep-paris.fr\/wp-content\/uploads\/2026\/10\/1118-scaled.jpg\" alt=\"\" \/><\/strong><\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n<\/section>\n<\/section>\n<\/section>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n<\/section>\n<\/section>\n<\/section>\n","protected":false},"excerpt":{"rendered":"<p>&#8220;The competition has provided us with a valuable platform to showcase our project, which is crucial for a company like ours that focuses on original drug research and development. At the same time, it has connected our company with many excellent resources,&#8221; said Ma Wenjiang, co-founder and CEO of Shanghai Shijiang Biotechnology Co., Ltd. \u00a0 When the seeds of innovation land in Shanghai, what kind of growth journey do they go through? Recently, at the finals of the 2025 &#8220;Innovate in Shanghai&#8221; International Innovation and Entrepreneurship Competition \u2014 guided by [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[37],"tags":[],"class_list":["post-540","post","type-post","status-publish","format-standard","hentry","category-2018-04-04-14-14-44"],"_links":{"self":[{"href":"https:\/\/www.saiep-paris.fr\/en\/wp-json\/wp\/v2\/posts\/540","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.saiep-paris.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.saiep-paris.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.saiep-paris.fr\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.saiep-paris.fr\/en\/wp-json\/wp\/v2\/comments?post=540"}],"version-history":[{"count":3,"href":"https:\/\/www.saiep-paris.fr\/en\/wp-json\/wp\/v2\/posts\/540\/revisions"}],"predecessor-version":[{"id":2526,"href":"https:\/\/www.saiep-paris.fr\/en\/wp-json\/wp\/v2\/posts\/540\/revisions\/2526"}],"wp:attachment":[{"href":"https:\/\/www.saiep-paris.fr\/en\/wp-json\/wp\/v2\/media?parent=540"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.saiep-paris.fr\/en\/wp-json\/wp\/v2\/categories?post=540"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.saiep-paris.fr\/en\/wp-json\/wp\/v2\/tags?post=540"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}